Jump to content

Pyoderma gangrenosum

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Doc James (talk | contribs) at 04:41, 30 August 2015 (trimmed). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pyoderma gangrenosum
SpecialtyDermatology Edit this on Wikidata

Pyoderma gangrenosum is a condition that causes tissue to become necrotic, causing deep ulcers that usually occur on the legs. When they occur, they can lead to chronic wounds. Ulcers usually initially look like small bug bites or papules, and they progress to larger ulcers. Though the wounds rarely lead to death, they can cause pain and scarring.

The disease was identified in 1930. It affects approximately 1 person in 100,000 in the population. Though it can affect people of any age, it mostly affects people in their 40s and 50s.[1]

Types

Pyoderma gangrenosum

There are two main types of pyoderma gangrenosum:[1]

  • the 'typical' ulcerative form, which occurs in the legs
  • an 'atypical' form that is more superficial and occurs in the hands and other parts of the body

Other variations are:[2]

Causes

Though the etiology is not well understood, the disease is thought to be due to immune system dysfunction, and particularly improper functioning of neutrophils. In support of an immune etiology, a variety of immune mediators such as IL-8, IL-1β, IL-6, interferon (IFN)-γ, G-CSF, TNF, matrix metallopaptidase (MMP)-9, MMP-10, and Elafin have all been reported to be elevated in patients with pyoderma gangrenosum.[5]

Also in support of an immune etiology is the finding that at least half of all pyoderma gangrenous patients suffer from immune-mediated diseases.[1] For instance, ulcerative colitis, rheumatoid arthritis, and multiple myeloma (MM) have all been associated with pyoderma gangrenosum. It can also be part of a syndromes such as PAPA syndrome.

One hallmark of pyoderma gangrenosum is pathergy, which is the appearance of new lesions at sites of trauma. [6]

Associations

The following are conditions commonly associated with pyoderma gangrenosum:[7]

Also granulomatosis with polyangiitis[9]

Treatment

First-line therapy for disseminated or localized instances of pyoderma gangrenosum is systemic treatment by corticosteroids and cyclosporine. Topical application of clobetasol, mupirocin, and gentamicin alternated with tacrolimus can be effective.

Papules that begin as small "spouts" can be treated with Dakins Solution to prevent infection and entire wounds cluster also benefit from this disinfectant. Wet to dry applications of Dakins can defeat spread of interior infection. Heavy drainage can be offset with Coban dressings. Grafting is not recommended due to tissue necrosis.

If ineffective, alternative therapeutic procedures include systemic treatment with corticosteroids and mycophenolate mofetil; mycophenolate mofetil and cyclosporine; tacrolimus; thalidomide; infliximab; or plasmapheresis.[10]

There is currently a phase III trial for the use of the IL-1B modulating agent gevokizumab in treating the ulcers of pyoderma gangrenosum. [11][12]

See also

References

  1. ^ a b c Jackson, J Mark; Callen, Jeffrey P (April 23, 2012). Elston, Dirk M (ed.). "Pyoderma Gangrenosum". Emedicine.
  2. ^ Brooklyn, T.; Dunnill, G; Probert, C (2006). "Diagnosis and treatment of pyoderma gangrenosum". BMJ. 333 (7560): 181–4. doi:10.1136/bmj.333.7560.181. PMC 1513476. PMID 16858047.
  3. ^ Shankar, S.; Sterling, J. C.; Rytina, E. (2003). "Pustular pyoderma gangrenosum". Clinical and Experimental Dermatology. 28 (6): 600–3. doi:10.1046/j.1365-2230.2003.01418.x. PMID 14616824.
  4. ^ Langan, Sinead M.; Powell, Frank C. (2005). "Vegetative pyoderma gangrenosum: A report of two new cases and a review of the literature". International Journal of Dermatology. 44 (8): 623–9. doi:10.1111/j.1365-4632.2005.02591.x. PMID 16101860.
  5. ^ Patel F, Fitzmaurice S, Duong C, He Y, Fergus J, Raychaudhuri SP, Garcia MS, Maverakis E (2015). "Effective strategies for the management of pyoderma gangrenosum: a comprehensive review". Acta Derm Venereol. 95 (5): 525–31. doi:10.2340/00015555-2008. PMID 25387526.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ Rashid, RM (2008). "Seat belt pyoderma gangrenosum: Minor pressure as a causative factor". Journal of the European Academy of Dermatology and Venereology. 22 (10): 1273–4. doi:10.1111/j.1468-3083.2008.02626.x. PMID 18837131.
  7. ^ Brooklyn, Trevor; Giles Dunnill; Chris Probert (2006). "Diagnosis and treatment of pyoderma gangrenosum". British Medical Journal. 333: 181–184. doi:10.1136/bmj.333.7560.181. PMC 1513476. PMID 16858047. {{cite journal}}: |access-date= requires |url= (help)
  8. ^ Tendas, Andrea (May 2011). "Tattoo related pyoderma/ectyma gangrenous as presenting feature of relapsed acute myeloid leukaemia: an exceptionally rare observation". Injury. 42 (5): 546–7. doi:10.1016/j.injury.2010.08.014. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  9. ^ Ponniah, I.; Shaheen, Ahmed; Shankar, K.A.; Kumaran, M.G. (2005). "Wegener's granulomatosis: The current understanding". Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 100 (3): 265–70. doi:10.1016/j.tripleo.2005.04.018. PMID 16122651.
  10. ^ Reichrath, Jörg; Bens, Guido; Bonowitz, Anette; Tilgen, Wolfgang (2005). "Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients". Journal of the American Academy of Dermatology. 53 (2): 273–83. doi:10.1016/j.jaad.2004.10.006. PMID 16021123.
  11. ^ https://clinicaltrials.gov/ct2/show/NCT02315417?term=gevokizumab+pyoderma+gangrenosum&rank=3
  12. ^ https://clinicaltrials.gov/ct2/show/NCT02326740?term=gevokizumab+pyoderma+gangrenosum&rank=2
Wikimedia Commons has media related to Pyoderma gangrenosum.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Pyoderma_gangrenosum&oldid=678560063"